Sartorius
Sartorius AG, a leading global partner of the biopharmaceutical industry, is headquartered in Göttingen, Germany. Founded in 1870, the company has established itself as a key player in the life sciences and laboratory equipment sectors, with significant operations across Europe, North America, and Asia. Sartorius specialises in providing innovative solutions for bioprocessing and laboratory applications, including high-precision balances, filtration systems, and bioreactors. Their commitment to quality and precision sets them apart in a competitive market. With a strong focus on sustainability and digitalisation, Sartorius has achieved notable milestones, including significant growth in revenue and market share. The company is recognised for its contributions to advancing biopharmaceutical manufacturing, making it a trusted name in the industry.
DitchCarbon Score
How does Sartorius's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sartorius's score of 52 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sartorius's reported carbon emissions
In 2023, Sartorius reported total carbon emissions of approximately 896,898 tonnes CO2e, comprising 13,103 tonnes (Scope 1), 26,823 tonnes (Scope 2), and about 856,972 tonnes (Scope 3). This reflects a significant commitment to reducing their carbon footprint, with a long-term goal of achieving net climate neutrality by 2045 across all scopes of emissions. Over the years, Sartorius has demonstrated a progressive increase in emissions, with total emissions recorded at 1,137,703 tonnes CO2e in 2022, 914,731 tonnes in 2021, and 43,156 tonnes in 2020. The company has set ambitious targets to mitigate its environmental impact, aiming for substantial reductions in both direct and indirect emissions. Sartorius's climate strategy includes a commitment to climate neutrality by 2045, which encompasses all scopes of emissions. This initiative aligns with industry standards and reflects a growing trend among companies in the pharmaceuticals and biotechnology sectors to prioritise sustainability and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 7,738,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,018,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sartorius is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
